Fresenius Medical Care AG & Co. KGaA CEO Net Worth

Last Updated Mar 10, 2025
CEO NameHelen Giza
NationalityGreek
Net Worth Estimation$15 million

Helen Giza's estimated net worth of around $15 million derives mainly from her executive compensation, stock awards, and incentives accumulated through her roles at Fresenius Medical Care AG & Co. KGaA and previous senior finance positions in major multinational corporations. Financial disclosures and industry reports indicate her earnings include performance-based bonuses, equity holdings, and long-term incentive plans tied to the company's valuation.

Helen Giza, CEO of Fresenius Medical Care AG & Co. KGaA, has an estimated net worth of $15,000,000, which is 6.25% above the healthcare CEO minimum and 83.3% below the maximum. Her net worth is closer to the lower end of the typical range for healthcare CEOs.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Helen Giza Performance in Fresenius Medical Care AG & Co. KGaA

Helen Giza, CEO of Fresenius Medical Care AG & Co. KGaA, demonstrates strategic leadership by driving innovation and operational efficiency in the global dialysis market. Her decision-making emphasizes sustainable growth and integration of advanced healthcare technologies, enhancing patient care quality and company competitiveness. Under her leadership, the company has seen improved financial performance and expanded market presence, solidifying its position as a leader in renal care services.


Latest News

Fresenius Medical Care Reports Strong Q3 2025 Growth and Leadership Updates

Fresenius Medical Care AG & Co. KGaA achieved a 28% operating income growth in Q3 2025, with all segments contributing to 10% organic revenue growth and margin expansion to 11.7%. CEO Helen Giza highlighted continued progress on the FME Reignite strategy, including share buybacks and Value-Based Care investments.
Source: http://www.prnewswire.com/news-releases/fresenius-medical-care-further-accelerates-organic-revenue-development-and-achieves-an-inflection-in-earnings-growth-delivering-28-operating-income-growth-in-the-third-quarter-of-2025-302603382.html



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Fresenius Medical Care AG & Co. KGaA are subject to change from time to time.

Comments

No comment yet